Ketoprofen etkileşimleri

…risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity… (Apiksaban etiketi, Kutulu uyarı)

Throughout this package insert, the term NSAID refers to a non-aspirin non-steroidal anti-inflammatory drug. (Ketoprofen etiketi, Kutulu uyarı)

Throughout this package insert, the term NSAID refers to a non-aspirin non-steroidal anti-inflammatory drug. (Ketoprofen etiketi, Kutulu uyarı)

Throughout this package insert, the term NSAID refers to a non-aspirin non-steroidal anti-inflammatory drug. (Ketoprofen etiketi, Kutulu uyarı)

Throughout this package insert, the term NSAID refers to a non-aspirin non-steroidal anti-inflammatory drug. (Ketoprofen etiketi, Kutulu uyarı)

…the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity… (Dabigatran etiketi, Kutulu uyarı)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

…the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity… (Edoksaban etiketi, Kutulu uyarı)

Avoid SYMFI with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple non-steroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.3) ] . (Efavirenz, lamivudin ve tenofovir etiketi, Uyarılar ve önlemler)

COMPLERA should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.4) ]. (Emtrisitabin, rilpivirin ve tenofovir etiketi, Uyarılar ve önlemler)

…the risk of developing epidural or spinal hematomas in these patients include: Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity… (Enoksaparin etiketi, Kutulu uyarı)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

…risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants • a history of traumatic or repeated epidural or spinal puncture • a history of spinal deformity… (Fondaparinuks etiketi, Kutulu uyarı)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

Unexpectedly severe and fatal gastrointestinal toxicity can occur with concomitant administration of XATMEP (primarily at high dosage) and nonsteroidal anti-inflammatory drugs (NSAIDs) [see Drug Interactions ( 7.1 )] . (Metotreksat etiketi, Uyarılar ve önlemler)

MISOPROSTOL SHOULD NOT BE TAKEN BY PREGNANT WOMEN TO REDUCE THE RISK OF ULCERS INDUCED BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) (see CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). (Misoprostol etiketi, Kutulu uyarı)

Patients with known aspirin sensitivity should continue to avoid aspirin or non-steroidal anti-inflammatory agents while taking SINGULAIR ( 5.4 ). (Montelukast etiketi, Uyarılar ve önlemler)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

Throughout this package insert, the term NSAID refers to a non-aspirin non-steroidal anti-inflammatory drug. (Ketoprofen etiketi, Kutulu uyarı)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

Avoid coadministration with probenecid or nonsteroidal anti-inflammatory drugs. (Pralatreksat etiketi, İlaç etkileşimleri)

Additional risk factors for bleeding include: body weight <60 kg, propensity to bleed, concomitant use of medications that increase the risk of bleeding (e.g . , warfarin, heparin, fibrinolytic therapy, chronic use of nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Warnings and Precautions (5.1) ] . (Prasugrel etiketi, Kutulu uyarı)

Therefore, the combination of ketoprofen and probenecid is not recommended. (Ketoprofen etiketi, Uyarılar ve önlemler)

Therefore, the combination of ketoprofen and probenecid is not recommended. (Ketoprofen etiketi, Uyarılar ve önlemler)

…risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity… (Rivaroksaban etiketi, Kutulu uyarı)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

Nephrotoxic agents Concomitant administration of cidofovir injection and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and nonsteroidal anti-inflammatory agents] is contraindicated. (Sidofovir etiketi, İlaç etkileşimleri)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

VIREAD should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple non-steroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.1) ] . (Tenofovir etiketi, Uyarılar ve önlemler)

Ketoprofen Capsules, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (Ketoprofen etiketi, Kontrendikasyonlar)

However, this is of special importance in patients at risk of or having underlying renal dysfunction and patients taking concomitant nephrotoxic agents such as cyclosporine, tacrolimus, aminoglycosides, vancomycin and non-steroidal anti-inflammatory drugs [See Adverse Reactions (6.2) and Clinical Pharmacology (12.3) ]. (Adefovir etiketi, Uyarılar ve önlemler)

Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (Afatinib etiketi, Uyarılar ve önlemler)

Use caution when co-prescribing aspirin/nonsteroidal anti- inflammatory drugs that may worsen gastrointestinal irritation. (Alendronat etiketi, İlaç etkileşimleri)

…part on the activity of the RAAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or patients receiving ARB, ACEI or nonsteroidal anti-inflammatory drug (NSAID), including selective Cyclooxygenase-2 inhibitors (COX-2 inhibitors), therapy may be at particular risk for developing acute renal failure… (Aliskiren etiketi, Uyarılar ve önlemler)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Ketoprofen etiketi, Uyarılar)

A second form of renal toxicity has been seen in patients with conditions leading to a reduction in renal blood flow or blood volume, where renal prostaglandins have a supportive role in the maintenance of renal blood flow. (Ketoprofen etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. (Ketoprofen etiketi, Uyarılar ve önlemler)

This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

• Increased exposure of amlodipine when coadministered with CYP3A inhibitors Olmesartan medoxomil ( 7.2 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS) may lead to increased risk of renal impairment and loss of antihypertensive effect. (Amlodipin ve olmesartan etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) : In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including valsartan, may… (Amlodipin ve valsartan etiketi, İlaç etkileşimleri)

Monitor patients for bleeding, including those receiving concomitant therapy with other drugs known to cause bleeding (e.g., anticoagulants, PDE3 inhibitors, NSAIDs, antiplatelet agents, selective serotonin reuptake inhibitors) [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (Anagrelid etiketi, Uyarılar ve önlemler)

Patients receiving Ketoprofen Capsules, USP who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants, should be carefully monitored. (Ketoprofen etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. (Ketoprofen etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. (Ketoprofen etiketi, Uyarılar ve önlemler)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

Non-steroidal Anti-Inflammatory Agents, including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or who have compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including azilsartan,… (Azilsartan etiketi, İlaç etkileşimleri)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (Balsalazid etiketi, İlaç etkileşimleri)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone. (Ketoprofen etiketi, Uyarılar ve önlemler)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

A second form of renal toxicity has been seen in patients with conditions leading to a reduction in renal blood flow or blood volume, where renal prostaglandins have a supportive role in the maintenance of renal blood flow. (Ketoprofen etiketi, Uyarılar ve önlemler)

Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone. (Ketoprofen etiketi, Uyarılar ve önlemler)

Patients receiving Ketoprofen Capsules, USP who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants, should be carefully monitored. (Ketoprofen etiketi, Uyarılar ve önlemler)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. (Ketoprofen etiketi, Uyarılar ve önlemler)

…↔ ↔ Valsartan (320 mg) 20 mg ↓12% [↓3%, ↓20%] ↔ Simvastatin (40 mg) 20 mg ↔ ↔ Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg ↓7% [↓22%, ↑11%] ↓22% [↓27%, ↓17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg ↑13% [↑3%, ↑24%] ↑51% [↑44%, ↑58%] ↔ = no change (geometric… (Dapagliflozin etiketi, İlaç etkileşimleri)

The risk of GI hemorrhage may be increased when administering Exjade in combination with drugs that have ulcerogenic or hemorrhagic potential, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants. (Deferasiroks etiketi, Uyarılar ve önlemler)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

…Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (Desmopressin etiketi, İlaç etkileşimleri)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

• Increased Risk of Bleeding: Concomitant use of aspirin, NSAIDs, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.4 ). (Desvenlafaksin etiketi, Uyarılar ve önlemler)

A second form of renal toxicity has been seen in patients with conditions leading to a reduction in renal blood flow or blood volume, where renal prostaglandins have a supportive role in the maintenance of renal blood flow. (Ketoprofen etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (Donepezil etiketi, Uyarılar ve önlemler)

Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (Drospirenon ve etinilestradiol etiketi, Uyarılar ve önlemler)

Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anti-coagulants may add to this risk. (Duloksetin etiketi, Uyarılar ve önlemler)

Patients taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents including non-steroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions. (Elvitegravir, kobisistat, emtrisitabin ve tenofovir etiketi, Uyarılar ve önlemler)

Individuals taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents including non-steroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions. (Emtrisitabin ve tenofovir etiketi, Uyarılar ve önlemler)

This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone. (Ketoprofen etiketi, Uyarılar ve önlemler)

This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. (Ketoprofen etiketi, Uyarılar ve önlemler)

A second form of renal toxicity has been seen in patients with conditions leading to a reduction in renal blood flow or blood volume, where renal prostaglandins have a supportive role in the maintenance of renal blood flow. (Ketoprofen etiketi, Uyarılar ve önlemler)

Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Risk factors for bleeding include older age, a history of bleeding disorders, and concomitant use of drugs that increase the risk of bleeding (thrombolytics, oral anticoagulants, nonsteroidal anti-inflammatory drugs, and P2Y 12 inhibitors). (Eptifibatid etiketi, Uyarılar ve önlemler)

Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (Erlotinib etiketi, Uyarılar ve önlemler)

Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (Essitalopram etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. (Ketoprofen etiketi, Uyarılar ve önlemler)

In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (Febuksostat etiketi, Uyarılar ve önlemler)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

Non-steroidal anti-inflammatory drugs The C max and AUC of flurbiprofen were increased by 23% and 81%, respectively, when coadministered with fluconazole compared to administration of flurbiprofen alone. (Flukonazol etiketi, İlaç etkileşimleri)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

Use with NSAIDs, aspirin, warfarin, or other drugs that affect coagulation may potentiate the risk of gastrointestinal or other bleeding ( 5.7 ) (Fluoksetin etiketi, Uyarılar ve önlemler)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (Fluvoksamin etiketi, Uyarılar ve önlemler)

This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone. (Ketoprofen etiketi, Uyarılar ve önlemler)

Diuretics NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients. (Ketoprofen etiketi, Uyarılar ve önlemler)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (Galantamin etiketi, Uyarılar ve önlemler)

Drug Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, ACE inhibitors, disopyramide, fluoxetine, clarithromycin, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking… (Glibenklamid etiketi, İlaç etkileşimleri)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (Glimepirid etiketi, İlaç etkileşimleri)

…angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory agents, chloramphenicol, probenecid, coumarins, voriconazole, H2 receptor antagonists, and quinolones. (Glipizid etiketi, İlaç etkileşimleri)

Glipizide: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. (Glipizid ve metformin etiketi, Önlemler)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

Patients receiving Ketoprofen Capsules, USP who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants, should be carefully monitored. (Ketoprofen etiketi, Uyarılar ve önlemler)

Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone. (Ketoprofen etiketi, Uyarılar ve önlemler)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. (İbandronat etiketi, İlaç etkileşimleri)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. (Ketoprofen etiketi, Uyarılar ve önlemler)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and COX-2 inhibitors: Increased risk of renal impairment. (İrbesartan etiketi, İlaç etkileşimleri)

Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone. (Ketoprofen etiketi, Uyarılar ve önlemler)

Nonsteroidal Anti-Inflammatory Drugs Meloxicam Concomitant drug dose increase may be necessary. (İtrakonazol etiketi, İlaç etkileşimleri)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (Kandesartan etiketi, İlaç etkileşimleri)

Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone. (Ketoprofen etiketi, Uyarılar ve önlemler)

This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

A second form of renal toxicity has been seen in patients with conditions leading to a reduction in renal blood flow or blood volume, where renal prostaglandins have a supportive role in the maintenance of renal blood flow. (Ketoprofen etiketi, Uyarılar ve önlemler)

This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone. (Ketoprofen etiketi, Uyarılar ve önlemler)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (Klopidogrel etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. (Ketoprofen etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. (Ketoprofen etiketi, Uyarılar ve önlemler)

A second form of renal toxicity has been seen in patients with conditions leading to a reduction in renal blood flow or blood volume, where renal prostaglandins have a supportive role in the maintenance of renal blood flow. (Ketoprofen etiketi, Uyarılar ve önlemler)

In patients taking ARAVA, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (Leflunomid etiketi, İlaç etkileşimleri)

Non-Steroidal Anti-Inflammatory Drugs The concomitant administration of a non-steroidal anti-inflammatory drug with a fluoroquinolone, including Levofloxacin in 5% Dextrose Injection, may increase the risk of CNS stimulation and convulsive seizures [see Warnings and Precautions (5.4) ]. (Levofloksasin etiketi, İlaç etkileşimleri)

Increased Risk of Bleeding : Concomitant use of NSAIDs, aspirin, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Levomilnasipran etiketi, Uyarılar ve önlemler)

This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone. (Ketoprofen etiketi, Uyarılar ve önlemler)

Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. (Ketoprofen etiketi, Uyarılar ve önlemler)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (Losartan etiketi, İlaç etkileşimleri)

Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone. (Ketoprofen etiketi, Uyarılar ve önlemler)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (Memantin ve donepezil etiketi, Uyarılar ve önlemler)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (Mesalazin etiketi, İlaç etkileşimleri)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. (Ketoprofen etiketi, Uyarılar ve önlemler)

Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone. (Ketoprofen etiketi, Uyarılar ve önlemler)

When given concomitantly with mifepristone, drugs that are substrates of CYP2C8/2C9 (including non-steroidal anti-inflammatory drugs, warfarin, and repaglinide) should be used at the smallest recommended doses, and patients should be closely monitored for adverse effects. [See Clinical Pharmacology ( 12.3 )] 7.5 Drugs Metabolized by CYP2B6 Mifepristone is an… (Mifepriston etiketi, İlaç etkileşimleri)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (Milnasipran etiketi, Uyarılar ve önlemler)

This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Although not observed with moxifloxacin in preclinical and clinical trials, the concomitant administration of a nonsteroidal anti-inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions [see Warnings and Precautions ( 5.4 ), and Patient Counseling Information ( 17 )]. (Moksifloksasin etiketi, İlaç etkileşimleri)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

Table 2: Clinically Significant Drug Interactions with Nateglinide Drugs That May Increase the Blood-Glucose-Lowering Effect of Nateglinide and Susceptibility to Hypoglycemia Drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone),… (Nateglinid etiketi, İlaç etkileşimleri)

Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (Nintedanib etiketi, Uyarılar ve önlemler)

Non Steroidal Anti-Inflammatory Drugs The concomitant administration of a non-steroidal anti-inflammatory drug with a quinolone, including ofloxacin, may increase the risk of CNS stimulation and convulsive seizures (see WARNINGS and PRECAUTIONS , General ). (Ofloksasin etiketi, İlaç etkileşimleri)

Use with NSAIDs, aspirin, warfarin, or other drugs that affect coagulation may potentiate the risk of gastrointestinal or other bleeding ( 5.16 ) (Olanzapin ve fluoksetin etiketi, Uyarılar ve önlemler)

NSAID use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7.2 ). (Olmesartan etiketi, İlaç etkileşimleri)

Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone. (Ketoprofen etiketi, Uyarılar ve önlemler)

Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone. (Ketoprofen etiketi, Uyarılar ve önlemler)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulant drugs may increase risk. (Paroksetin etiketi, Uyarılar ve önlemler)

DRUG INTERACTIONS Bleeding has been reported in patients treated with pentoxifylline extended-release tablets with or without concomitant NSAIDs, anticoagulants, or platelet aggregation inhibitors. (Pentoksifilin etiketi, İlaç etkileşimleri)

This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (Pioglitazon ve glimepirid etiketi, İlaç etkileşimleri)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (Potasyum klorür etiketi, İlaç etkileşimleri)

Nonsteroidal Anti-inflammatory drugs (NSAIDs) monitor for hyperkalemia (7.4) (Potasyum sitrat etiketi, İlaç etkileşimleri)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

Monitor patients using rivastigmine tartrate for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (Rivastigmin etiketi, Uyarılar ve önlemler)

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): May lead to increased risk of renal impairment. (Sakubitril ve valsartan etiketi, İlaç etkileşimleri)

Drug Interactions As with other cephalosporins, cefotaxime may potentiate the nephrotoxic effects of nephrotoxic drugs such as aminoglycosides, NSAIDs and furosemide. (Sefotaksim etiketi, İlaç etkileşimleri)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (Sertralin etiketi, Uyarılar ve önlemler)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

In addition, concomitant use of NSAIDs with cyclosporine, particularly in the setting of dehydration, may potentiate renal dysfunction. (Siklosporin etiketi, İlaç etkileşimleri)

NSAIDs Use with caution Non-steroidal anti-inflammatory drugs (but not acetyl salicylic acid) in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies and in postmarketing. (Siprofloksasin etiketi, İlaç etkileşimleri)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk. (Sitalopram etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. (Ketoprofen etiketi, Uyarılar ve önlemler)

Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone. (Ketoprofen etiketi, Uyarılar ve önlemler)

Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including telmisartan, may… (Telmisartan etiketi, İlaç etkileşimleri)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (Telmisartan ve amlodipin etiketi, İlaç etkileşimleri)

Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone. (Ketoprofen etiketi, Uyarılar ve önlemler)

In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. (Teriflunomid etiketi, İlaç etkileşimleri)

Promptly evaluate patients treated with XELJANZ/XELJANZ XR who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis or taking NSAIDs) and who present with new onset abdominal symptoms for early identification of gastrointestinal perforation [see Adverse Reactions (6.1) ] . (Tofasitinib etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. (Ketoprofen etiketi, Uyarılar ve önlemler)

This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (Trazodon etiketi, Uyarılar ve önlemler)

A second form of renal toxicity has been seen in patients with conditions leading to a reduction in renal blood flow or blood volume, where renal prostaglandins have a supportive role in the maintenance of renal blood flow. (Ketoprofen etiketi, Uyarılar ve önlemler)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (Ketoprofen etiketi, Uyarılar ve önlemler)

Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. (Ketoprofen etiketi, Uyarılar ve önlemler)

Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone. (Ketoprofen etiketi, Uyarılar ve önlemler)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (Ketoprofen etiketi, Uyarılar)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (Upadasitinib etiketi, Uyarılar ve önlemler)

Non-Steroidal Anti-Inflammatory Drug (NSAID) use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7.2 ) (Valsartan etiketi, İlaç etkileşimleri)

Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone. (Ketoprofen etiketi, Uyarılar ve önlemler)

Warfarin The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone. (Ketoprofen etiketi, Uyarılar ve önlemler)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (Venlafaksin etiketi, Uyarılar ve önlemler)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.3 ) (Vilazodon etiketi, Uyarılar ve önlemler)

NSAIDs Non-Steroidal Anti-Inflammatory Drug including. ibuprofen and diclofenac (CYP2C9 Inhibition) Increased Frequent monitoring for adverse reactions and toxicity related to NSAIDs. (Vorikonazol etiketi, İlaç etkileşimleri)

• Increased Risk of Bleeding : Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, or other drugs that affect coagulation may increase risk ( 5.3 ). (Vortioksetin etiketi, Uyarılar ve önlemler)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (Zoledronik asit etiketi, İlaç etkileşimleri)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

It is possible that minor adverse symptoms of gastric intolerance may be prevented by administering Ketoprofen Capsules, USP with antacids, food, or milk. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

…angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions. (Finasterid etiketi, İlaç etkileşimleri)

Examples: Nonsteroidal anti-inflammatory agents and other highly protein-boind drugs, salicylcates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, beta-adrenergic blocking agents; potentially with ciprofloxacin, micronazole. (Glibenklamid ve metformin etiketi, İlaç etkileşimleri)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

In RA, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents (NSAIDs), folic acid, corticosteroids and/or narcotics. (İnfliksimab etiketi, İlaç etkileşimleri)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (Lenalidomid etiketi, Uyarılar ve önlemler)

Other drugs: Carbamazepine Furosemide (> 80 mg IV) Heparin Hydantoins Non-Steroidal Anti-Inflammatory Drugs - Fenamates These drugs may cause protein-binding site displacement. (Levotiroksin etiketi, İlaç etkileşimleri)

Other drugs: Carbamazepine Furosemide (>80 mg IV) Heparin Hydantoins Non-Steroidal Anti-inflammatory Drugs Fenamates These drugs may cause protein binding site displacement. (Liyotironin etiketi, İlaç etkileşimleri)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

Antacids Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Keoprofen Capsules, USP. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

It is possible that minor adverse symptoms of gastric intolerance may be prevented by administering Ketoprofen Capsules, USP with antacids, food, or milk. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (Repaglinid etiketi, İlaç etkileşimleri)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (Risedronat etiketi, İlaç etkileşimleri)

It is possible that minor adverse symptoms of gastric intolerance may be prevented by administering Ketoprofen Capsules, USP with antacids, food, or milk. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

Concomitant Drugs for Treatment of Adult Indications In RA patients, population pharmacokinetic analyses did not detect any effect of methotrexate (MTX), non-steroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance. (Tosilizumab etiketi, İlaç etkileşimleri)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

Digoxin In a study in 12 patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin. (Ketoprofen etiketi, Uyarılar ve önlemler)